PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Antiparasitic drugs - Market size and forecast 2018-2023 Antibacterial drugs - Market size and forecast 2018-2023 Antiviral drugs - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison ROW - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 North America - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Market trends PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bayer AG F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Novartis AG Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global infectious disease treatment market Exhibit 02: Segments of global infectious disease treatment market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Diseases caused by organisms Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Antiparasitic drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Antiparasitic drugs - Year-over-year growth 2019-2023 (%) Exhibit 22: Antibacterial drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Antibacterial drugs - Year-over-year growth 2019-2023 (%) Exhibit 24: Antiviral drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Antiviral drugs - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 31: ROW - Year-over-year growth 2019-2023 (%) Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Asia - Year-over-year growth 2019-2023 (%) Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 35: North America - Year-over-year growth 2019-2023 (%) Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Impact of drivers and challenges Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: Bayer AG - Vendor overview Exhibit 45: Bayer AG - Business segments Exhibit 46: Bayer AG - Organizational developments Exhibit 47: Bayer AG - Geographic focus Exhibit 48: Bayer AG - Segment focus Exhibit 49: Bayer AG - Key offerings Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 56: GlaxoSmithKline Plc - Vendor overview Exhibit 57: GlaxoSmithKline Plc - Business segments Exhibit 58: GlaxoSmithKline Plc - Organizational developments Exhibit 59: GlaxoSmithKline Plc - Geographic focus Exhibit 60: GlaxoSmithKline Plc - Segment focus Exhibit 61: GlaxoSmithKline Plc - Key offerings Exhibit 62: Novartis AG - Vendor overview Exhibit 63: Novartis AG - Business segments Exhibit 64: Novartis AG - Organizational developments Exhibit 65: Novartis AG - Geographic focus Exhibit 66: Novartis AG - Segment focus Exhibit 67: Novartis AG - Key offerings Exhibit 68: Pfizer Inc. - Vendor overview Exhibit 69: Pfizer Inc. - Business segments Exhibit 70: Pfizer Inc. - Organizational developments Exhibit 71: Pfizer Inc. - Geographic focus Exhibit 72: Pfizer Inc. - Segment focus Exhibit 73: Pfizer Inc. - Key offerings Exhibit 74: Validation techniques employed for market sizing Exhibit 75: Definition of market positioning of vendors  

Bayer AG F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Novartis AG Pfizer Inc.